Introduction
Breast cancer (BC) is the most common cancer type in women, and with an ageing population, its incidence is increasing [
1]. Although rare, BC also occurs in men, accounting for approximately 1% of all cancers in men [
2]. BC can be categorised according to the presence or absence of several receptors, allowing it to be classified into a number of subtypes. These include the estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone receptor (PR). Luminal A and luminal B breast cancers both express ER. Luminal B-like breast cancer is HER2 positive and ER positive. Basal-like or triple-negative breast cancer (TNBC) does not express any of these receptors. The subtype influences diagnosis, prognosis, and treatment of the tumour [
3].
ER is a nuclear hormone receptor that binds to estrogen in the cytoplasm and subsequently translocates into the nucleus to activate expression of estrogen responsive genes. 70–80% of BCs are ER-positive; thus, estrogen and ER are commonly targeted during treatment of this type of cancer. There are two isoforms of ER, alpha and beta, and activation of ER-α by estrogens is primarily responsible for enhanced proliferation in ER-positive BC. In contrast, ER-β has an antiproliferative effect and can counteract the tumorigenic effects of ER-α [
4]. Tamoxifen is a selective estrogen receptor modulator (SERM) that binds ER and induces conformational changes in the receptor that inhibits coactivator binding, and thus, prevents its activation. While tamoxifen reduces the mortality rate in ER-positive BC, acquired resistance due to long-term use is estimated to occur in approximately one third of patients [
5]. Hence, the risk of recurrence is of considerable clinical concern and leads to a need for novel and innovative ER-targeting treatments [
6].
Androgen receptor (AR) is also a nuclear receptor and mediates the effect of androgens by modulating the expression of genes involved in proliferation and survival. Androgen hormones and their receptor play a vital role in normal prostate development, but androgen receptor (AR) is also the main driver in the development of prostate cancer [
7].
AR also plays an important role in normal female biology including fertility and breast development. Moreover, it is expressed in 60–80% of breast tumours [
8]. Nearly 90% of ER-positive tumours express AR, but less than 30% of ER-negative breast cancers are AR positive. Outcomes for patients with ER-positive/AR-positive tumours are better than those with ER-negative/AR-positive tumours. This is believed to be due to AR competing with ER for binding to estrogen response elements, resulting in impaired transcription of estrogen-regulated genes [
9]. In contrast, in ER-negative breast cancers, AR signalling can drive tumour growth. ER activation has also been implicated in prostate cancer progression [
10]. Thus, therapeutic strategies that modulate the levels of these nuclear receptors could prove effective at delaying or preventing breast cancer progression.
Recent work from our laboratory has discovered that inhibition of the endosomal recycling of the HER2 receptor tyrosine kinase (RTK) leads to downregulation of its signalling, and ultimately to its degradation in lysosomes [
11]. Proteins in the plasma membrane are continuously internalised into organelles called early endosomes by a process called endocytosis. This is a means by which the cell controls the strength and duration of their signalling. From early endosomes, cell surface proteins can be returned to the plasma membrane along the endosomal recycling pathway to be re-used, or they are sent to lysosomes for degradation. The majority of endocytosed proteins are recycled back to the plasma membrane [
12]. We reported that a small molecule inhibitor of endosomal recycling, called primaquine (PQ), reduces the total protein levels of HER2 and synergises with HER2-targeting therapies. Furthermore, we showed that BC cells with acquired or innate resistance to HER2-targeted therapies have enhanced sensitivity to PQ [
11]. We demonstrated that when endosomal recycling is inhibited, internalised HER2 and its heterodimerisation partner, HER3, are diverted to lysosomes for degradation.
To gain a greater understanding of the mechanism of action of PQ, we performed a reverse-phase protein array (RPPA) assay to determine the effect that the drug has on the levels and activation status of approximately 450 proteins that have been implicated in cancer. Interestingly, we found that both ER-α and AR were downregulated in a HER2-amplified cell line that had been treated with PQ. Between 60 and 70% of HER2-positive breast cancers co-express hormone receptors and bidirectional crosstalk between the ER and HER2 signalling pathways has been well established in breast cancer [
13]. This has clinical consequences as co-expression of these receptors modulates tumour response to both HER2-targeting and endocrine therapies [
13]. Furthermore, activation of the ER signalling pathway has been reported as an escape mechanism for tumours that are subject to HER2 inhibition [
14].
We confirmed these findings in other hormone receptor-positive BC cell lines. We also show that endosomal recycling inhibitors synergise with tamoxifen, a standard-of-care therapy for BC. These results suggest that modulating the activity of the endosomal recycling pathway may be a useful strategy for downregulating the activity of hormone receptors in BC.
Materials and methods
Reagents
All cell culture media and supplements were purchased from Sigma-Aldrich (UK). Monensin, resazurin, and MG132 were from Sigma-Aldrich, and plasticware was from Sarstedt. Primaquine, lapatinib, enzalutamide, and MTT were purchased from Carbosynth, UK. BafA1 was obtained from Merck.
Antibodies specific for ER-α (#8644), AR (#5153), and HER3 (#12708) were from Cell Signalling Technology. Mouse monoclonal anti-alpha tubulin (T5168) was from Sigma-Aldrich. 680RD-conjugated goat anti-Mouse (C80619-5) and 800CW-conjugated goat anti-Rabbit (C80426-08) secondary antibodies were from LI-COR Biosciences.
Reverse phase protein array (RPPA)
BT474 cells were seeded in a 6-well plate at 5 × 105 cells per well and cultured until the cells had reached 70–80% confluency. The medium was replaced with 2 ml fresh culture medium with or without 10 µM PQ. 24 h later the cells were washed twice with cold PBS and lysed in lysis buffer (1% TX-100; 50 mM Hepes, pH 7.4; 150 mM NaCl; 1.5 mM MgCl2; 1 mM EGTA, 100 mM NaF; 10 mM Na pyrophosphate, 1 mM Na3VO4; 10% glycerol) plus protease inhibitors. Cell and nuclear debris were removed by centrifugation at 20,000 xg. The protein concentration was determined by Bradford assay and adjusted to 1.5 µg/µl with lysis buffer and mixed with 4X Sample buffer plus β-mercaptoethanol, but without bromophenol blue. The cells were heat denatured, snap-frozen, and two biological replicates for each condition were sent on dry ice to the MD Anderson Cancer Center RPPA Core Facility (TX, USA) for RPPA analysis. Protein levels were determined by interpolation of dilution curves to give log2 values. The data were then normalised for protein loading and transformed to linear values. Normalised linear values were transformed to log2 values, and heat maps were generated using Java Treeview.
Cell culture
The human breast cancer cell line MCF-7 (ATCC) was cultured in Dulbecco’s Modified Eagle Medium (DMEM). MDA-MB-134 VI and SUM44-PE cells were cultured in RPMI 1640 media. Authenticated BT474 cells were purchased from CalTag Medsystems and cultured in DMEM. Media were supplemented with 10% foetal bovine serum, 1% L-glutamine, and 1% penicillin–streptomycin. Cells were cultured at 37 °C in a humidified atmosphere at 5% CO2. All cell lines were regularly checked for mycoplasma contamination by fluorescence microscopy using DAPI staining or with MycoAlert Mycoplasma Detection Kit (Lonza).
To knockdown HER3 expression, two independent siRNA duplexes were purchased (Sigma). A siRNA duplex targeting firefly luciferase was used as a negative control (siFLUC). Reverse transfections were performed with a final siRNA concentration of 20 nM using Lipofectamine RNAiMax (Thermo Fisher), according to the manufacturer’s instructions. Cell lysates were prepared 72 h post-transfection.
Cell viability assays
MTT assay
The MTT assay was used to assess cell viability of cells grown in 2D. 72 h post-drug treatment, MTT (Carbosynth, UK) was added to the cells and incubated for 2–3 h at 37 °C. The cells were solublised with MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol). The OD570 and OD630 was measured on a MultiSkan Go plate reader (Thermo Scientific). Quadruplicate wells for each treatment were analysed, and each experiment was carried out at least 3 times.
IC50 and synergy
The IC
50 values were determined by nonlinear regression of the dose–response data using GraphPad Prism 9.4.1 for PC (GraphPad Software, La Jolla, CA). Synergy was determined by the method of Chou and Talalay [
15,
16]. In brief, cells were exposed to 1:1 ratios of the IC
50 values of hormone antagonist and endosomal recycling inhibitor at 1/8 × IC
50, ¼ × IC
50, ½ × IC
50, IC
50, 2 × IC
50, and 4 × IC
50. Cell viability was determined after 72 h treatment, and the CI was calculated using the CompuSyn software [
17], to determine the presence of synergism (CI < 1) or antagonism (CI > 1).
Clonogenic assays
10,000 MCF-7 cells were seeded into each well of a 12-well plate. After 24 h, medium was replaced with fresh medium containing the respective drug. Media/drug solution was replaced every 3–4 days. Plates were incubated for a total of 10 days. Following drug treatment, the cells were washed with warmed PBS and living cells were stained with 0.5% crystal violet in 20% methanol. Plates were scanned on a flatbed scanner, and ImageJ was used to quantify colonies.
Immunoblot analysis
Whole cell lysates were prepared in RIPA buffer supplemented with phosphatase and protease inhibitors (10 mM NaF + 1 mM NaOV + 1X PIC + 10 mM Na.pyrophosphate + AEBSF + 10 mM β-glycerophosphate). Cells were incubated in the RIPA solution on ice for > 20 min. Lysates were centrifuged at 14,000 rpm to remove cellular and nuclear debris. Bradford assay was used to determine protein concentration, and samples were heat denatured for 5 min at 95 °C in 4X loading buffer.
SDS-PAGE was used to resolve equal amounts of proteins, and the proteins were transferred to nitrocellulose. Revert 700 Total Protein stain (LI-COR Biosciences, UK) was used to reversibly stain the nitrocellulose membranes. Membranes were scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences, UK). After washing off the Revert, membranes were blocked with Odyssey Blocking Buffer TBS at room temperature for approximately one hour. Primary antibodies were diluted in Odyssey Blocking Buffer TBS, and membranes were incubated with the primary antibody at 4 °C overnight. IRDye-conjugated secondary antibodies were used for detection with the Odyssey system. Secondary antibody incubation was carried out for one hour. LI-COR Image Studio software was used for densitometry, and bands were normalised against the Revert 700 stain for that sample, according to the manufacturer’s instructions.
RT-qPCR
100,000 MCF-7 cells/well were seeded in a 12-well plate. After 48 h, wells were treated for 24 h with the appropriate drug in 1 ml media. Total RNA was extracted using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, #SLCD5747). The extracted RNA samples were reversed transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, #163,017,287). The cDNA obtained was then quantitatively amplified using real-time PCR with FastStart Essential DNA Green Master (Roche) ready-to-use SYBR Green I reaction mix on a Roche LightCycler 96 instrument.
Cancer genomics
ERBB2 (HER2),
ERBB3 (HER3),
ESR1 (ER-α), and
AR gene expression in the 68 breast cancer cell lines available in the Cancer Cell Line Encyclopedia (CCLE) were determined, and the median gene expression for
ERBB3 or
ERBB2 was used to divide the datasets into high (above median) and low (below median) expressing groups. The same strategy was used to analyse 1903 breast tumours from the METABRIC study available in the cBioPortal database [
18,
19].
The protein levels of ER-α, AR, HER2, and HER3 in breast cancer cell lines available in the DepMap Portal database were downloaded and imported into GraphPad Prism where they were subjected to a simple linear regression analysis.
Data analysis
Statistical significance was determined using the Student’s t-test, or where specified a 1-way analysis of variance, using GraphPad Prism. Significance was classified as a P-value of * < 0.05, ** < 0.01, *** < 0.001.
Discussion
Tamoxifen, a drug which inhibits the estrogen receptor, has been used for decades to treat ER-positive breast cancer. Although initially effective, long-term use of tamoxifen has led to approximately 40% of patients developing acquired resistance to this therapy [
36]. Thus, new drugs and drug combinations are urgently required that target ER and AR, to overcome this drug resistance.
A novel approach to treating cancer could involve inhibition of the endosomal recycling pathway. Defective endosomal recycling has been implicated in the development and progression of many cancer types, including breast and prostate cancer, and since this pathway is frequently hyperactivated in cancer, a therapeutic dose of an endosomal recycling inhibitor is less likely to affect non-malignant cells [
12]. We and others have shown that clinically relevant cell surface proteins such as EGFR, HER2, HER3, N-cadherin, and c-Met, are downregulated when endosomal recycling is inhibited [
11,
21,
37‐
40].
There are several small molecules that inhibit the endosomal recycling pathway, including PQ and monensin [
20,
41], and we recently reported that PQ blocks the recycling of HER2 and HER3 back to the plasma membrane in HER2-positive breast cancer [
11]. To gain a greater understanding of the mechanism of action of PQ, we performed a reverse-phase protein array assay using BT474 HER2-positive BC cells to identify proteins and signalling pathways that are altered by PQ treatment. Among the top 30 hits were the hormone receptors ER-α and AR, both of which were downregulated by PQ. We validated these findings by Western blot and then moved to investigate if PQ and monensin could also downregulate ER-α and AR in other BC cancer cell lines. We observed a dose-dependent reduction of the hormone receptors in all BC cell lines tested. Further, we have recently reported similar effects in prostate cancer cells [
42].
PQ downregulates HER3 by blocking its trafficking back to the plasma membrane and diverting it to lysosomes where it is degraded. The PQ-induced downregulation of HER3 can be rescued by cotreating cells with a lysosomal inhibitor [
11]. However, we were unable to restore hormone receptor levels with lysosomal or proteasomal inhibitors, suggesting that the effect of the ERIs on these proteins occurs by a different mechanism. Quantitative reverse transcriptase PCR showed that the downregulation occurred at the transcriptional level, likely as a downstream consequence of the lysosomal degradation of HER3.
ERBB and hormone receptor signalling pathways overlap, and approximately two thirds of HER2 + breast cancers also express hormone receptors. The presence of ER-α influences the response to HER2-targeted therapies while HER2 expression impacts the efficacy of endocrine therapies [
13]. Given this crosstalk, we reasoned that there may be a feedback loop that regulates the expression of components of these pathways. MCF-7 cells express high levels of HER3 and minimal levels of EGFR and HER2 (Fig.
S2A and [
11]), and we observed that both PQ and monensin downregulate HER3 protein levels in these cells (not shown). To investigate if the downregulation of ER-α and AR is an indirect consequence of the ERIs inducing the lysosomal degradation of HER3, we explored cancer genomics databases to determine if there is a correlation between HER3 and hormone receptor expression. We observed a strong positive correlation between HER3 and both ER-α and AR expression in breast cancer cell lines and breast tumours. Furthermore, knockdown of HER3 resulted in a consistent and reproducible reduction in ER-α levels. The effect on AR was more variable. These findings suggest that HER3 regulates ER-α and possibly AR gene expression, and that the effect of PQ and monensin on the hormone receptors is a downstream consequence of the lysosomal degradation of HER3.
HER3 expression has been implicated in resistance to tamoxifen. A study of more than 400 patients with tamoxifen-treated ER-positive breast cancer found that patients whose tumours were also positive for HER2 and HER3 are more likely to relapse while on tamoxifen than those with HER2- and HER3-negative tumours [
43]. In addition, siRNA-mediated knockdown of HER3 sensitises breast cancer cell lines to tamoxifen [
44]. We investigated whether indirectly downregulating HER3 by inhibiting its endosomal recycling would enhance the efficacy of tamoxifen. Using cell viability and clonogenic assays, we observed that ERIs synergised with tamoxifen in a number of BC cells, including the tamoxifen-resistant invasive lobular carcinoma MDA-MB-134 VI cell line.
Primaquine was approved by the FDA in 1952 to treat patients with malaria and is, thus, a readily available and cost-effective drug with a good safety profile [
45]. Therefore, we believe that PQ has the potential to be repurposed as a combination treatment to enhance the efficacy of hormone receptor antagonists and to reduce the emergence of drug resistance. Monensin is a sodium ionophore approved for use as a veterinary medication with a narrow therapeutic window. The FDA has not approved it for use in humans as monensin intoxication can lead to renal failure, rhabdomyolysis, and cardiac failure [
46]. Nevertheless, many studies in recent years have demonstrated its potential as a cancer therapeutic [
47‐
51]. Indeed, monensin has been previously reported to reduce the expression of AR in prostate cancer cell lines and to synergise with the anti-androgen flutamide [
52]. We have found that ERIs also downregulate AR and synergise with enzalutamide in prostate cancer [
42]. Given that monensin displayed strong effects at nanomolar concentrations, with further research and possible modification of its chemical structure monensin could also have clinical utility for the treatment of hormone receptor-positive cancer patients. Since the ERIs do not act directly on the hormone receptors, tumour cells are less likely to develop resistance to these drugs.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.